The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for CRISPR Therapeutics AG's 9-Day RSI or its related term are showing as below:
CRSP's 9-Day RSI is ranked better than 75.39% of 1422
companies
in the Biotechnology industry
Industry Median: 50.12
vs CRSP: 40.93
CRISPR Therapeutics AG (NAS:CRSP) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
CRISPR Therapeutics AG 9-Day RSI Related Terms
CRSP vs ORKA, TVTX, MANE: 9-Day RSI Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 9-Day RSI falls into.
CRISPR Therapeutics AG (NAS:CRSP) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (CRSP) has a 9-Day RSI of 40.93 as of Jul. 13, 2026. According to the industry distribution chart, CRISPR Therapeutics AG ranks #350 out of 1422 companies in the Biotechnology industry, placing it in the top 24.6%.
Is CRISPR Therapeutics AG's 9-Day RSI too high?
CRISPR Therapeutics AG's current 9-Day RSI is 40.93. The Biotechnology industry median 9-Day RSI is 50.12. CRISPR Therapeutics AG's value of 40.93 is 18.3% below this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #350 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's 9-Day RSI compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #350 out of 1422 companies for 9-Day RSI. This places CRISPR Therapeutics AG in the top 25% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 50.12. CRISPR Therapeutics AG's value of 40.93 is 18.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current 9-Day RSI of 40.93 is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current 9-Day RSI is 40.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.37, compared to a current price of $51.97 — trading 1442.1% above its estimated fair value. The current 9-Day RSI is 40.93 and 18.3% below the Biotechnology industry median of 50.12. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current 9-Day RSI is 40.93 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $51.97 is trading 1442.1% above its estimated GF Value™ of $3.37.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
9-Day RSI: 40.93
GF Value™: $3.37 vs. price of $51.97 (1442.1% above fair value)
Industry Position: 18.3% below the Biotechnology median (#350 of 1422)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 